Misspecification of at‐risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation. (14th December 2016)

• Record Type: Journal Article
• Authors: Law, M.; Sweeting, M.J.; Donaldson, G.C.; Wedzicha, J.A.
• Is Part Of: Pharmaceutical statistics. Volume 16:Number 3(2017)
• Page Start: 201
• Page End: 209
• Publication Date: 2016-12-14
• Subjects: chronic obstructive pulmonary disease -- exacerbation rate -- negative binomial -- recurrent events; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1798
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract : In trials comparing the rate of chronic obstructive pulmonary disease exacerbation between treatment arms, the rate is typically calculated on the basis of the whole of each patient's follow‐up period. However, the true time a patient is at risk should exclude periods in which an exacerbation episode is occurring, because a patient cannot be at risk of another exacerbation episode until recovered. We used data from two chronic obstructive pulmonary disease randomized controlled trials and compared treatment effect estimates and confidence intervals when using two different definitions of the at‐risk period. Using a simulation study we examined the bias in the estimated treatment effect and the coverage of the confidence interval, using these two definitions of the at‐risk period. We investigated how the sample size required for a given power changes on the basis of the definition of at‐risk period used. Our results showed that treatment efficacy is underestimated when the at‐risk period does not take account of exacerbation duration, and the power to detect a statistically significant result is slightly diminished. Correspondingly, using the correct at‐risk period, some modest savings in required sample size can be achieved. Using the proposed at‐risk period that excludes recovery times requires formal definitions of the beginning and end of an exacerbation episode, and we recommend these be always predefined in a trial protocol.